WS
COGT icon

Wedbush Securities’s Cogent Biosciences COGT Stock Holding History

Wedbush Securities’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-8,284
Closed -$24K – 904
2019
Q4 		$24K Hold
8,284
– – ﹤0.01% 981
2019
Q3 		$48K Buy
+8,284
New +$67.3K ﹤0.01% 940

Other funds holding COGT

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Wedbush Securities's COGT Position: Q1 2020 in Review

Wedbush Securities sold out of Cogent Biosciences (COGT) in Q1 2020, closing a stake of 8,284 shares — an estimated $24K sold.

Wedbush Securities first reported a position in COGT in Q3 2019 and held it in 2 quarters. The position peaked at $48K in Q3 2019. 25 funds tracked by Wall St. Rank hold COGT as of Q1 2020.

  • Wedbush Securities reported no remaining Cogent Biosciences position as of Q1 2020 after selling out during the quarter.
  • Wedbush Securities sold 8,284 Cogent Biosciences shares in Q1 2020, an estimated $24K.
  • Wedbush Securities first reported a position in Cogent Biosciences in Q3 2019 and held it in 2 quarters.
  • Wedbush Securities's Cogent Biosciences position peaked at $48K in Q3 2019.
  • 25 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2020.

Based on Wedbush Securities's 13F filing for Q1 2020, filed 17 Apr 2020.